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to assess neurocognitive function was administered before 
and 1 month after the procedure.
Results Nineteen patients (54 %) developed new cer-
ebral ischemic lesions after carotid artery stenting. Contrast 
enhancement of the plaque was greater in the patients with 
post-procedural microembolization than in those without it 
[maximum signal intensity 26 ± 7.7 vs. 21 ± 5.2, respec-
tively, (p = 0.039), mean signal intensity, 20.7 ± 6.1 vs. 
16.5 ± 5.3, respectively (p = 0.048)]. No correlation was 
found between neurocognitive test scores and microembo-
lization or plaque enhancement.
Conclusion Contrast enhancement of the carotid plaque 
is strongly associated with post-procedural microemboliza-
tion and for this reason it can be considered a reliable tool 
for an accurate selection of patients undergoing this endo-
vascular treatment. However, the neurocognitive test scores 
performed in this study are not enough sensible to appre-
ciate the impact of the neurological injury on the day life 
activities.
Keywords Contrast-enhanced ultrasound · Diffusion-
weighted magnetic resonance imaging · Carotid artery 
stenting · CEUS · CAS · Microembolization
Background and purpose
Cerebral microembolization, one of the most frequent side 
effects of carotid artery stenting (CAS), occurs in 10–40 % 
of cases [1]. It is mainly due to the accidental embolization 
from the aortic arch or during the crossing of the internal 
carotid stenosis with the guide wires and catheters or due to 
the plaque morphology (soft ulcerated plaques are at higher 
risk) during stent deployment [2]. The clinical impact 
of neurological injury and cognitive decline after CAS is 
Abstract 
Objectives Cerebral microembolization, one of the most 
frequent complications of carotid artery stenting, is asso-
ciated with an increased risk of peri- and post-procedural 
stroke and transient ischemic attack and a mid-term risk of 
neurocognitive decline. A valuable tool to evaluate carotid 
plaque instability and risk of embolization is contrast-
enhanced ultrasound. With this prospective study we sought 
to determine the correlation between contrast enhancement 
of the plaque and cerebral microembolization after carotid 
stent deployment and to evaluate the clinical impact of the 
neurological injury.
Materials and methods Thirty-five consecutive patients 
with carotid artery stenosis and indications for endovascu-
lar stenting were enrolled. Before the procedure, patients 
were evaluated with contrast-enhanced ultrasound to define 
plaque enhancement (signal intensity). All endovascular 
procedures were performed under cerebral filter protection. 
Diffusion-weighted magnetic resonance imaging scans to 
detect microemboli were obtained before and 48 h after 
the stent deployment. The Ray auditory verbal learning test 
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still unclear because, in addition to the presence of many 
potential confounders, neurologic assessment often fails 
to capture and predict changes in cognitive function [3, 4]. 
A valuable technique to define plaque enhancement and 
potential risk of embolization is contrast-enhanced ultra-
sound (CEUS) [5–8], while diffusion-weighted magnetic 
resonance imaging (DW-MRI) is a highly reliable imag-
ing method for detecting recent ischemic brain lesions [9]. 
The aim of this study is to compare plaque enhancement 
as evaluated by CEUS with new cerebral ischemic lesions 
after CAS and to define the clinical impact of the neuro-
logical injury.
Methods
The prospective study has been approved by an ethic com-
mittee and it has been performed in accordance with the 
ethical standards laid down in the Declaration of Helsinki 
and its later amendments. All patients gave their informed 
consent prior to their inclusion in the study. We enrolled 
35 consecutive patients (28 males, 7 females; mean age 
73.2 ± 5) treated with CAS for severe carotid artery steno-
sis. Three patients (8 %) were symptomatic before the pro-
cedure [transient ischemic attack (TIA) with left hemiple-
gia in 2, and dysarthria and transient right arm paresthesia 
in 1].
Inclusion criteria
Degree of carotid stenosis >70 % according to North 
American Symptomatic Carotid Endarterectomy Trial 
(NASCET) or with a peak of systolic velocity >200 cm/s; 
symptomatic and asymptomatic patients; contraindication 
to carotid endoarterectomy.
Exclusion criteria
Secondary carotid artery stenting; occlusion of the ipsi-
lateral middle cerebral artery (MCA); cerebral imaging of 
haemorragic stroke; patients with neurological impairment 
>15 according to National Institute of Health Stroke Score 
(NIHSS).
The indications for CAS were: history of neck radio-
therapy (n = 3); previous neck surgery (n = 5); patient’s 
personal choice (n = 12); anatomically unfavourable bifur-
cation (n = 3); contralateral vocal cord paralysis (n = 2); 
and medical/anaesthesiological contraindication to open 
surgery (n = 10) (Table 1).
Imaging and cognitive assessment
Preoperative echo-Doppler ultrasound scans (MyLab 
25Gold, Esaote®) were obtained to define plaque morphol-
ogy and measure the degree of stenosis [10], followed by 
CEUS to evaluate plaque enhancement. Preoperative neu-
rologic assessment included head magnetic resonance 
(MR) examination (Philips Achieva 1.5 T, head coil) 
and neuropsychological test [Ray auditory verbal learn-
ing test (RAVLT)]. The MR protocol was performed with 
T1-weighted sagittal, T2-weighted axial, fluid-attenuated 
inversion recovery (FLAIR) axial and diffusion-weighted 
imaging (DWI) with quantitive analysis using apparent 
diffusion coefficient (ADC) maps. Ischemic lesions of the 
cerebral hemispheres, size, and location were recorded and 
analyzed by a single operator.
Table 1  Characteristics and cardiovascular risk factors of the study population divided between patients who developed post procedural cerebral 
ischemic injury (Microembolization+) and those without post-procedural ischemic injury (Microembolization−)
Total Microembolization+ Microembolization− p value
Number of patients 35 19 (54 %) 16 (46 %)
Age 73.2 ± 5 72.8 ± 5.14 73.5 ± 6.4 0.45
Hypertension 27/35 (77 %) 15/19 (78 %) 12/16 (75 %) 0.79
Smoke 12/35 (36 %) 4/19 (21 %) 8/16 (50 %) 0.08
Diabetes 8/35 (23 %) 3/19 (15 %) 5/16 (31 %) 0.31
Dyslipidemia 19/35 (54 %) 12/19 (63 %) 7/16 (43 %) 0.27
Chronic renal failure 3/35 (8 %) 1/19 (5 %) 2/16 (12 %) 0.51
Chronic obstructive pulmunary disease 2/35 (5 %) 2/19 (10 %) 0/16 (0 %) 0.28
Miocardial infarction 8/35 (23 %) 3/19 (16 %) 5/16 (31 %) 0.31
Stroke/TIA before CAS 3/35 (8 %) 2/19 (10 %) 1/16 (6 %) 0.71
Degree of stenosis 77 ± 4.5 77 ± 4.2 76 ± 4.8 0.46
Periferial arteriopaty 15/35 (42 %) 9/19 (47 %) 6/16 (37 %) 0.58
Ischemic lesions before CAS 9/35 (25 %) 4/19 (21 %) 5/16 (31 %) 0.52
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CAS procedure
Angiography was performed in local anesthesia after 
the administration of a load dose of 300 mg clopidogrel, 
through a percutaneous femoral access; a cerebral protec-
tion filter (SpiderFX®, Covidien, Plymouth, MN) was then 
deployed into the internal carotid downstream the stenosis. 
CAS was performed with a Bard Vivexx® stent (Bard, New 
Providence, NJ) in 30 cases, a Carotid Wallstent® (Boston 
Scientific, Natick, MA) in 3 and an Xact® (Abbott Vascu-
lar, Redwood City, CA) in 2. Postprocedural hemostasis 
was achieved with manual compression. A 1-month course 
of double antiplatelet therapy [clopidogrel 75 mg and ace-
tylsalicylic acid (ASA) 100 mg] was initiated, followed by 
lifelong single antiaggregation therapy with ASA.
Postprocedural patient evaluation and follow‑up
Before discharge, a second DW-MRI study was performed 
48 h after CAS to detect potentially new brain ischemic 
lesions. Follow-up examination included echo-Doppler 
ultrasonography (at 1, 6, 12 months, and then yearly there-
after) performed by the same operator and clinical and cog-
nitive evaluation (RAVLT) at 1 month after the procedure.
Data collection and statistical analysis
All data from CEUS, DW-MRI and RAVLT scores were 
collected blinded of the other results to avoid any con-
founders. CEUS images were analyzed with Quontrast 4.0® 
dedicated software (Bracco, Milan, Italy), as described 
in a previous study [5], and the maximum and mean sig-
nal intensity (SI max and SI mean) were calculated. Pre 
and post procedural DW-MRI images were compared to 
detect the presence of new ischemic lesions and to define 
the side (ipsilateral-contralateral), size, location, and num-
ber (Fig. 1). Moreover, we determined a cut-off value for 
SI max and SI mean with Cohen k and we confirmed the 
results with the maximization of the harmonic mean of the 
data distribution.
Primary end-points of the study are: the correlation 
between the carotid plaque enhancement (CEUS) with 
post-procedural cerebral embolization (DW-MRI) and 
to evaluate the the clinical impact of the neurological 
ischemic injury (DW-MRI) on the procedural and memory 
cerebral functions (RAVLT).
Secondary end-points are: the technical success of the 
procedure, post-procedural neurological complications and 
the rate of restenosis at 1 year of follow up.
Fig. 1  a Contrast enhancement 
of a carotid vulnerable plaque 
(dashed line region of interest 
ROI). b Analysis of the same 
plaque with Quontrast® above 
a color map representing in 
red the area of higer enhance-
ment and in green the area of 
lower enhancement, below 
computer assisted evaluation 
of CEUS pattern with SI max 
and SI mean calculation. c, d 
Comparison between pre- and 
post-procedural DW-MRI of 
the same patient showing new 
microembolization areas (red 
arrows)
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For the statistical analysis, the variables, reported as 
mean ± standard deviation (SD), were compared with the 
non-parametric Mann–Whitney test. The categorical vari-
ables, reported as counts and percentages with 95 % con-
fidence interval, arranged in row × column contingency 
tables, were analyzed with the Chi square test (with Yates’ 
correction for 2 × 2) or Fisher’s exact test. The risk ratio 
(RR) was computed with its 95 % confidence interval (CI). 
Statistical significance was set at p < 0.05. For p > 0.05, 
the test power and relative false negative probability were 
estimated.
Results
The degree of stenosis, measured according to NAS-
CET and as evaluated with echo-Doppler ultrasound, was 
77 ± 4.5 %. CAS was technically successful in all patients; 
no residual stenosis, carotid dissection, elastic recoil or 
stent fracture was seen on the postprocedural angiography 
images. DW-MRI revealed silent ischemic brain lesions in 
nine patients (25 %) before CAS. The postprocedural DW-
MRI control scans detected new ipsilateral ischemic lesions 
(from 1 to 5 lesions) in 19 patients (54 %). Neurologic 
postprocedural complications arose in two patients (6 %): 
one case of facial paresthesia which completely regressed 
before hospital discharge and one case of contralateral bra-
chial weakness and numbness which partially resolved at 
6-months and totally regressed at one year follow-up. Com-
parison of the CEUS images showed a statistical difference 
in the SI max and SI mean between the patients with and 
those without microembolization [SI max 26 ± 7.7 vs. 
21 ± 5.2, respectively (p = 0.039), SI mean 20.7 ± 6.1 vs. 
16.5 ± 5.3, (p = 0.048), respectively]. Afterwards we per-
formed the ROC curve for SI max and SI mean with an area 
under the curve (AUC) of 0.72 (0.55–0.88) and 0.67 (0.49–
0.85), respectively. Results revealed a SI max cut-off value 
of 26 and SI mean cut-off value of 20. In particular for SI 
max we found a statistical difference between the patients 
with values above 26 compared to those with values below 
the cut off with an increased risk of microembolization of 
81 % (p = 0.03). The difference for SI mean values was not 
statistically significant (p = 0.2) (Table 2).
At 30 days, follow up with echo-Doppler ultrasound, we 
found two patients (5 %) with a moderate degree of intra-
stent restenosis that remained stable at 6 months and 1 year 
control. There was no statistically significant variation of 
RAVLT scores for the patients with post-procedural micro-
embolization (8 ± 4.6 before CAS vs. 8 ± 5.5 after CAS; 
p = 0.53) or for those without it (7.4 ± 5.4 before CAS vs. 
7.7 ± 4 after CAS; p = 0.62).
Discussion
There is a growing body of evidence that CEUS evaluation 
of carotid artery lesions can be a cost-effective and reli-
able method to define plaque vulnerability and predict the 
risk of embolization [5, 6, 11]. Because of the significantly 
higher risk of periprocedural embolization during primary 
CAS as compared with carotid endoarterectomy, CEUS can 
be advantageously applied as a useful imaging system for 
Table 2  Results of the study between patients who developed post procedural cerebral ischemic injury (Microembolization+) and those without 
post-procedural ischemic injury (Microembolization−)
* p value <0.05. Below the SI max and SI mean values we reported the distribution of the study population according to the cut-off estimated for 
each variable. RAVLT p value was evaluated in the same group before and after CAS
Total Microembolization+ Microembolization− p value
Number of patients 35 19 16
Technical success of CAS procedure 35 (100 %) 19/19 (100 %) 16/16 (100 %) –
Neurologic post-procedural complication 2/35 (5 %) 2/19 (10 %) 0/16 (0 %) 0.28
SI max – 26 ± 7.7 21 ± 5.2 0039*
 >26 9 2 0.03*
 26 10 14
SI mean – 20.7 ± 6.1 16.5 ± 5.3 0048*
 >20 10 4 0.2
 20 9 12
1 year restenosis 2/35 (5 %) 1/19 (5 %) 1/16 (6 %) 0.51
RAVLT
 Before CAS 8 ± 4.6 7.4 ± 5.4
 After CAS 8 ± 5.5 7.7 ± 4
 p value 0.53 0.62
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the assessment of plaque morphology [12]. Stent deploy-
ment exerts strong radial forces on arterial walls, augment-
ing the risk of plaque fragmentation and cerebral emboli-
zation. Unfortunately, even the systematic use of cerebral 
protection filters appears to be insufficient to prevent this 
complication [13]. DW-MRI is a highly sensitive method 
for the early detection of ischemic brain regions by virtue 
of its ability to identify cytotoxic edema, one of the first 
hallmarks of brain injury [9]. Data from the literature sug-
gest that, as compared with traditional carotid endarterec-
tomy, postprocedural microembolization is associated with 
faster neurocognitive decline particularly in memory func-
tion [3, 4]. Therefore, we compared neuropsychological 
RAVLT score before CAS and at 1-month follow-up.
We found a direct association between plaque enhance-
ment and postprocedural microembolization, which is con-
sistent with our previous findings on plaque vulnerability 
and with published data [5, 6]. In detail, patients with a SI 
max value of more than 26 have a significantly higher risk 
of developing cerebral microembolization with CAS. The 
cut-off values of SI mean do not reach statistical signifi-
cance (p = 0.2) however the distribution of values reveal a 
trend towards a difference between the two groups and this 
result might be attributable to the small population size.
We found no correlation between CEUS results and the 
number of the cerebral lesions or a significant difference 
between the number of lesions and clinically relevant neu-
rological symptoms. This could be partially explained by 
the presence of silent parenchymal brain regions or hemo-
dynamic mechanisms of brain compensation (“washout” 
phenomenon) [14, 15]. The RAVLT scores failed to reveal 
a decline in memory function in patients with microembo-
lization at 1 month follow-up. This finding contrasts with 
previous observations [3, 4] and is partially attributable 
to the specific neurocognitive domain investigated, and 
patient compliance. To the best of our knowledge, this is 
the first study that directly compares CEUS evaluation of 
the carotid plaque with CAS post-procedural microembo-
lization. Despite the relatively small sample size, our data 
are supported by a high statistical significance. As this is an 
ongoing study, it is important to confirm these results on a 
larger population study and to investigate other neurocogni-
tive domains with multiple tests and for a longer follow-up.
Conclusion
Contrast enhancement of the atherosclerotic plaque is 
strongly associated with the risk of microembolization 
after carotid stenting deployment. For this reason CEUS 
could become a mandatory assessment to select patients 
who benefit most from CAS. Further neurological tests are 
recommended to appreciate the clinical impact of the cer-
ebral ischemic damage after the procedure.
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